From CAR-T to CAAR-T: Funding drives biotech into emerging space

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/baiploo)
(Image: Getty/baiploo)

Related tags: CAR-T, T cell, T cell receptor, T cells, Finance, Biotech companies, Biotechnology

Cabaletta Bio closed a $50m Series B funding enabling the company to develop further in the CAAR-T space.

The $50m (€43.8m) Series B financing will support the establishment of translational research and advanced manufacturing capabilities.

Cabaletta Bio, a biotechnology company, will use these capabilities to accelerate the development of its product pipeline.

Additionally, Cabaletta stated that the funds will be used to support the IND submission for DSG3-CAAR-T, and the initiation of its first clinical trial in patients with mucosal pemphigus vulgaris upon clearance by the US Food and Drug Administration.

Chimeric antigen receptor T-cells (CAR-T) is a form of immunotherapy that uses a patient’s modified T cells to produce chimeric antigen receptors on their surface. Chimeric autoantibody receptor (CAAR) T-cells, work similarly but produce a chimeric autoantibody receptor on the surface of the T-cell to exhibit cytotoxicity against specific cells, such as autoreactive B cells in antibody-mediated autoimmune disease.

After the recent $50m funding, the company has raised $88m in total since May of 2018, according to Steven Nichtberger, CEO and chairman of Cabaletta.

Nichtberger told us, “From our series A round, Cabaletta was already sufficiently funded to reach clinical proof of concept in the DSG-CAART program.  The additional funding will support the parallel development of additional products for patients, and consequently further secure Cabaletta’s leadership position in this new CAAR space.”

Related news

Follow us

Products

View more

Webinars